Investigating how HMGA1 proteins contribute to aggressive leukemia and treatment resistance
Official title: Role of the chromatin regulator HMGA1 in KMT2A-rearranged leukemia
Funded at Johns Hopkins University · NIH-11161139 · Data updated 2026-11-12
This study is looking at how a protein called HMGA1 affects a tough type of leukemia called KMT2A-rearranged acute myeloid leukemia, with the goal of finding better treatment options for patients who often struggle with current therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | April 3, 2024 |
| Project end | April 2, 2027 |
| Funding year | 2025 |
| Award (this year) | $49,538 |
| NIH project number | 5F31CA284842-02 |
| Project ID | NIH-11161139 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with KMT2A-rearranged acute myeloid leukemia who are experiencing treatment resistance.
✕Less likely to help
Patients with other types of leukemia or those who do not have KMT2A rearrangements may not benefit from this research.
What this research studies
This research focuses on understanding the role of HMGA1 proteins in KMT2A-rearranged acute myeloid leukemia (AML), a severe form of leukemia that often does not respond to existing treatments. The study aims to uncover the mechanisms by which HMGA1 influences the development of leukemia and its resistance to therapies. By analyzing the behavior of HMGA1 in leukemia cells, researchers hope to identify new therapeutic strategies that could improve treatment outcomes for patients with this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that are more effective for patients with KMT2A-rearranged AML.
How similar studies have gone: While there have been studies on KMT2A-rearranged leukemia, the specific focus on HMGA1 as a therapeutic target is a novel approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: West, Bailey — Johns Hopkins University
- Study coordinator: West, Bailey
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.